# Therapeutic Potential of Lactobacillus rhamnosus DS3316 via Cell Apoptosis in Colorectal Cancer

## TL;DR

This study explores how a specific strain of Lactobacillus, called DS3316, can help fight colorectal cancer by causing cancer cell death without harming normal cells.

## Contribution

The study identifies Lactobacillus rhamnosus DS3316 as a potential microbiome-based therapy for colorectal cancer.

## Key findings

- Lactobacillus rhamnosus DS3316 inhibits the growth of colorectal cancer cell lines.
- RNA-seq analysis shows increased apoptosis-related gene activity in treated cancer cells.
- The strain is non-toxic to human iPSC-derived intestine organoids.

## Abstract

Colorectal cancer (CRC) has a very high mortality rate worldwide. Although various therapies have been developed to treat CRC, the need for novel therapeutic approaches has been increasing due to severe side effects and limited efficacy of current treatments. Recently, although research on the gut microbiome and its association with colon cancer has been growing, the mechanisms of gut microbiome inhibition in CRC remain insufficiently understood. Thus, in this study, we investigated the growth-inhibitory effects of the culture supernatant of Lactobacillus rhamnosus DS3316, isolated from infant feces, on CRC cell lines (HCT116 and SNUC5). And RNA-seq analysis revealed an increase in apoptosis-related terms induced by L. rhamnosus DS3316 treatment. Also, we found the non-toxicity of L. rhamnosus DS3316 in human iPSC-derived intenstine organoid. Thus, we suggested that L. rhamnosus DS3316 inhibits the growth of colorectal cancer cell lines without affecting normal cells. And L. rhamnosus DS3316 is expected to be a promising candidate for the development of microbiome-based colorectal cancer therapies. Furthermore, its combined use with various colorectal cancer treatment methods could lead to the proposal of more effective therapeutic approaches.